Screening populations at low risk carries high risksBMJ 2003; 326 doi: http://dx.doi.org/10.1136/bmj.326.7379.53 (Published 04 January 2003) Cite this as: BMJ 2003;326:53
- Luc Bonneux, associate professor ([email protected])
- Julius Center for Health Sciences, Utrecht Medical Center, HP D 01.335, PO Box 85500NL-3508 GA Utrecht, Netherlands
EDITOR—In their key points Lu-Yao et al say that the lack of association between more intensive screening and treatment and lower mortality from prostate cancer means that trials should continue to settle this question.1 More research is the classic conclusion of all studies, but is it true?
Firstly, trials cannot be used to prove that something does not work. That is unethical; there has to …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial